tradingkey.logo
tradingkey.logo

Stereotaxis Inc

STXS
1.775USD
-0.115-6.08%
Close 03/30, 16:00ETQuotes delayed by 15 min
10.96MMarket Cap
LossP/E TTM

Stereotaxis Inc

1.775
-0.115-6.08%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Stereotaxis Inc

Currency: USD Updated: 2026-03-27

Key Insights

Stereotaxis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 108 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.20.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Stereotaxis Inc's Score

Industry at a Glance

Industry Ranking
108 / 208
Overall Ranking
257 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Stereotaxis Inc Highlights

StrengthsRisks
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.94% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 32.38M.
Fairly Valued
The company’s latest PE is -7.22, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.95M shares, decreasing 3.54% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 5.27K shares of this stock.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
4.200
Target Price
+122.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Stereotaxis Inc is 6.19, ranking 162 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 8.64M, representing a year-over-year increase of 36.31%, while its net profit experienced a year-over-year increase of 25.39%.

Score

Industry at a Glance

Previous score
6.19
Change
0

Financials

6.03

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.10

Operational Efficiency

5.15

Growth Potential

5.61

Shareholder Returns

7.08

Stereotaxis Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Stereotaxis Inc is 6.86, ranking 140 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -7.22, which is -28.46% below the recent high of -5.17 and -74.14% above the recent low of -12.58.

Score

Industry at a Glance

Previous score
6.86
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 108/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Stereotaxis Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 4.00, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
4.200
Target Price
+130.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Stereotaxis Inc
STXS
5
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Stereotaxis Inc is 6.77, ranking 65 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.20 and the support level at 1.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.00
Change
-0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(4)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
0.004
Neutral
RSI(14)
36.135
Neutral
STOCH(KDJ)(9,3,3)
31.175
Sell
ATR(14)
0.098
Low Volatility
CCI(14)
-105.113
Sell
Williams %R
85.765
Oversold
TRIX(12,20)
-0.701
Sell
StochRSI(14)
21.844
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.830
Sell
MA10
1.829
Sell
MA20
1.926
Sell
MA50
2.123
Sell
MA100
2.283
Sell
MA200
2.471
Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Stereotaxis Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 47.09%, representing a quarter-over-quarter increase of 2.89%. The largest institutional shareholder is The Vanguard, holding a total of 3.69M shares, representing 3.80% of shares outstanding, with 7.62% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Fischel (Nathan)
13.92M
+0.31%
Dafna Capital Management, LLC
13.68M
--
Kiani (Joe E)
8.86M
+5.07%
Lagoda Investment Management, L.P.
4.71M
+0.42%
BlackRock Institutional Trust Company, N.A.
3.68M
+2.13%
The Vanguard Group, Inc.
Star Investors
3.44M
+4.19%
2012 Revocable Trust of Andrew Redleaf
3.08M
--
Arbiter Partners Capital Management, LLC
2.85M
--
Isaac (Paul J)
2.06M
+0.49%
Geode Capital Management, L.L.C.
1.51M
+2.13%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Stereotaxis Inc is 2.88, ranking 140 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.88
Change
0
Beta vs S&P 500 index
1.42
VaR
+5.88%
240-Day Maximum Drawdown
+49.86%
240-Day Volatility
+62.94%

Return

Best Daily Return
60 days
+8.05%
120 days
+12.26%
5 years
+33.14%
Worst Daily Return
60 days
-6.43%
120 days
-14.74%
5 years
-26.46%
Sharpe Ratio
60 days
-1.71
120 days
-1.55
5 years
-0.17

Risk Assessment

Maximum Drawdown
240 days
+49.86%
3 years
+50.00%
5 years
+86.04%
Return-to-Drawdown Ratio
240 days
+0.19
3 years
+0.04
5 years
-0.18
Skewness
240 days
+0.25
3 years
+1.14
5 years
+0.53

Volatility

Realised Volatility
240 days
+62.94%
5 years
+71.81%
Standardised True Range
240 days
+7.02%
5 years
+9.79%
Downside Risk-Adjusted Return
120 days
-229.11%
240 days
-229.11%
Maximum Daily Upside Volatility
60 days
+45.70%
Maximum Daily Downside Volatility
60 days
+36.46%

Liquidity

Average Turnover Rate
60 days
+0.57%
120 days
+0.52%
5 years
--
Turnover Deviation
20 days
+53.23%
60 days
+40.10%
120 days
+27.80%

Peer Comparison

Healthcare Equipment & Supplies
Stereotaxis Inc
Stereotaxis Inc
STXS
6.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI